Analyst consensus rating
Evommune Analyst Rating: Buy
EVMN is rated Buy by 7 analysts with a $27.57 target. As of 2026-08-19.
Direct answer
Evommune's consensus rating is Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $27.57.
Forecast evidence checked August 19, 2026.
Get free Evommune email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $14.22
- Average price target
- $27.57
- High price target
- $32.00
- Low price target
- $22.00
- Low target gap
- +54.7%
- Target upside
- +93.9%
- High target gap
- +125%
- Target range width
- 70.3%
- Consensus rating
- Buy
- Analysts
- 7
- Evidence date
- August 19, 2026
- Valid through
- August 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Evommune?
Evommune has a verified Buy consensus. The same dataset has an average price target of $27.57.
How far are Evommune's low and high targets from the recorded price?
The low target implies +54.7%, while the high target implies +125%.
How many analysts are included in Evommune's consensus?
The verified consensus includes 7 analysts.
How is Evommune's target upside or downside calculated?
The average target of $27.57 is divided by the recorded price of $14.22, then one is subtracted to produce +93.9%. This does not guarantee a future return.
When was Evommune's analyst forecast verified?
The data was verified on 2026-08-19. The dataset is valid through 2026-08-26.